Moderna

Moderna is the company that made one of the two big COVID vaccines. That vaccine (Spikevax) made them billions, but as COVID fades from the headlines, investors are asking: what's next? The answer is ambitious. Moderna is using the same mRNA technology — which essentially teaches your cells to make proteins that trigger an immune response — to attack much bigger markets. Their flu vaccine could replace the old-fashioned egg-grown vaccines your doctor gives you every fall. Their combo shot would let you get both your flu and COVID vaccine in a single visit. And their cancer vaccine, developed with Merck, is perhaps the most exciting: it's custom-built for each patient's specific tumor mutations. Here's what makes Moderna interesting for investors right now: the stock is down significantly from its pandemic highs, but the pipeline has never been stronger. They have $9.5 billion in cash, they're already selling an approved RSV vaccine, and they have three potentially massive products in late-stage trials. If even two of these work, the stock has substantial upside from current levels. The risk? All of this is still unproven outside COVID. The flu market is brutally competitive. The cancer vaccine, while promising, is years from peak revenue. And Moderna burns through about $3 billion a year. This is a company with blockbuster potential but real execution risk.